In venture capital, you often hear about the next app, the next SaaS platform, the next “productivity tool.” At Hard2beat, we’re wired a bit differently. We look for tech that touches the real world, and every so often, we encounter a tech that matters when life hangs in the balance.
Pikralida is one of those companies.
We invested because Pikralida is tackling medical emergencies where current medicine leaves a critical gap. Stroke, traumatic brain injury, and venomous snakebites may seem unrelated at first glance, but they share one defining feature: acute, rapidly progressing damage that today’s tools cannot stop.
Pikralida is already a clinical-stage biotech, with its lead molecule tested in humans and preparing for multiple Phase II programs. That is exceptionally rare at this stage – and it changes everything. Science is not theoretical. The safety profile is not hypothetical. The foundation is real.
But what truly stood out to us was the company’s strategy. Pikralida is building two high-impact programs from one coherent mechanism:
- Neuroprotection – addressing the destructive cascade that follows stroke and TBI.
- Snakebite envenoming – stopping venom-driven tissue destruction in humans and animals.
Both represent areas of profound unmet need, yet each offers a different commercial pathway: one long-term and transformative, the other fast-to-market with early revenue potential.
This combination – clinical readiness, a rediscovery-driven mechanism, acute indications, and a staged commercial strategy – is not something we see often. And that’s why we joined Pikralida’s financing round – a round worth roughly PLN 12.5M (about EUR 3M), with our fund as part of the investor group. What convinced us wasn’t just the science, but the idea at the core of it: giving patients and doctors something they’ve always lacked – protection in those first critical hours.
The Rediscovery of Marimastat - and Why We Think It’s Brilliant
In biotech, most innovation starts at the bottom of the mountain: new chemistry, new toxicology packages, years of uncertainty just to find out whether a molecule is even safe in humans. Pikralida chose a different path – one makes the company unusual, and unusually compelling.
Their lead molecule, PKL-021 (marimastat), was once one of the most promising MMP inhibitors developed in oncology. It never reached the market, not because it lacked biological power, but because oncology demanded the one thing it couldn’t deliver: chronic, uninterrupted dosing over months or years. In long-term use, marimastat triggered toxicity – a dealbreaker for cancer, where patients must take a drug continuously. The mechanism was sound. The context was wrong.
What Pikralida recognised is that a molecule can fail in one setting and still hold enormous potential in another. In acute, time-critical conditions – where treatment lasts hours or days, not months – marimastat’s former limitations fall away and its strengths become highly valuable. It is potent. It acts quickly. And, crucially, it is already clinically characterised, with human safety and pharmacokinetics well established.
This is the real power of drug rediscovery: not repurposing a marketed drug, but re-evaluating a well-studied, never-commercialised molecule with fresh assumptions, and deploying it where the biology and dosing finally align.
For early-stage biotech, rediscovery is a quiet superpower. It compresses timelines, lowers development risk, and frees capital to focus on demonstrating efficacy rather than re-proving basic safety. It gives a young company something rare: a credible, accelerated path into Phase II.
Instead of climbing the entire mountain, Pikralida chose a better route – one that leads to real patients, real products, and real value much faster.
Neuroprotection program (Stroke & TBI)
Rediscovery allowed Pikralida to pair an already characterised molecule with the indication where it can create the greatest value: neuroprotection, a field with enormous unmet need and no approved therapies.
When a stroke or TBI happens, the dangerous part isn’t just the initial event. Inside the brain, a rapid chain reaction begins. The body releases MMP-9, an enzyme that breaks down the blood–brain barrier – the brain’s protective lining. Once this barrier opens, swelling increases, inflammation rises, toxins enter injured tissue, and neurons start to die.
This “second wave” of damage is what often determines long-term disability. And today, medicine has no way to stop it.
Stroke care focuses on reopening a vessel. TBI care focuses on stabilising the patient. But the destructive cascade that unfolds just afterwards the event continues unchecked. Pikralida wants to fill exactly this gap.
Their candidate, PKL-021, is designed to work during the narrow window when the brain needs protection most. By blocking MMP-9 early, it aims to keep the blood–brain barrier intact, limit swelling and inflammation, and reduce the loss of neurons.
Importantly, Pikralida brought the molecule through its own development pathway. With Phase I successfully completed, the company now moves forward as a clinical-stage biotech preparing its next clinical steps.
The plan is clear:
- TRX-03 in ischemic stroke – preparation for Phase II clinical trials now underway
- TRX-01 in traumatic brain injury – positioned for advancement through a joint-venture partnership, given its scale and strategic importance to both civilian and defence medicine, and ready to enter Phase II once the partnership is in place
The goal is simple and ambitious: give doctors a tool to protect the brain before the damage becomes irreversible.
Snakebite envenoming program: The Race Against Venom and Time
Pikralida’s strategy doesn’t rely on neurology alone. The same mechanism behind their neuroprotection program also applies to another acute, high-impact medical problem: snakebite envenoming.
Snakebites may sound niche, but the scale is global and severe – millions of bites each year, causing over 100,000 deaths and more than 500,000 long-term complications. And the problem is not limited to rural parts of Africa or Asia. In the United States alone, hundreds of thousands of dogs are bitten annually, and human cases remain a significant challenge in southern states.
Antivenom saves lives, but it has clear limits. It must be given intravenously and in a hospital, and it does nothing to stop the early tissue destruction that begins in the first minutes after a bite. In many cases, reaching a hospital takes hours – hours during which venom metalloproteinases continue to cause progressive, irreversible damage. Even in the United States, with well-developed emergency systems, only around 40% of patients walk away from viperid snakebites with relatively minor consequences. In less-resourced regions, getting to clinical care can take far longer than a few hours, and the damage by the time antivenom is administered is often severe.
Why does PKL-021 fit here? Because venom from viperid snakes – relies heavily on snake venom metalloproteinases to rapidly destroy tissue and blood vessels. It is the same type of acute, enzymatic damage seen in the brain after stroke or TBI. And PKL-021 blocks these enzymes.
This insight led Pikralida to develop two complementary projects:
- TRX-06 – an oral therapy for humans, which has completed Phase I and is now being prepared for Phase II to slow venom-driven tissue destruction and coagulation disorders in the critical minutes after a bite.
- TRX-12 – a veterinary drug for pets, which face a high incidence of snakebites in regions like the US. The veterinary regulatory pathway is significantly faster and more cost-efficient, creating a near-term commercial opportunity.
With TRX-12 expected to reach the US market in 2027/2028, Pikralida has created a pipeline in which early veterinary revenues can help fuel the larger, longer neurology trials. It’s a smart pairing: one mechanism, two urgent medical needs, and a balanced commercial strategy that reduces capital pressure while increasing impact.
The US Navy, Snakebites, and Real-World Dual-Use
Pikralida’s work is not just relevant to healthcare systems. It also has clear applications in defence and security, where TBI or snakebites remain a very real operational risk.
TBI is one of the most common injuries in training and deployment settings – from blast exposure to impact trauma – and there is no approved therapy that protects the brain in the early hours. Pikralida’s TBI candidate, TRX-01, is built for exactly that moment. Because of the scale of the opportunity and its strategic importance, the company is developing TRX-01 with the intention of forming a joint venture: a partnership that combines business, science, and public-sector capabilities to bring a neuroprotective therapy where it is needed most.
Snakebites pose a different but equally practical challenge for armed forces, border patrol units, and their working dogs. Operations often take place in rugged, remote terrain where venomous snakes are common and access to IV antivenom is limited.
This is precisely why Pikralida’s work attracted the attention of the US Navy. The company entered a CRADA (Cooperative Research and Development Agreement) with the Navy’s Naval Medical Research Unit (NAMRU) San Antonio to co-develop small-molecule, field-ready treatments that can be given immediately after a bite to slow tissue destruction and reduce the need for dangerous evacuations. For a Polish biotech, securing such a partnership is exceptional – and a strong validation of both the science and the strategy.
In both TBI and envenoming, the unmet need is the same: fast-acting intervention in environments where hospital-level care is hours away. This is the essence of dual use in Pikralida’s case – one scientific mechanism, applied to two high-impact problems in both civilian medicine and defence readiness – each with a clear path to real operational value.
People Who Can Actually Pull This Off
Great science isn’t enough without a team that can execute. Pikralida has one of the strongest teams we’ve seen.
Dr. Stanisław Pikul – the CEO Co-founder, brings deep expertise across the entire drug development spectrum – from early discovery through preclinical work and into clinical development. Before founding Pikralida, he helped build OncoArendi (now Molecure) and played a key role in developing a drug licensed to Galapagos NV. At the time, it was the largest deal of its kind in Polish biotech – a landmark partnership worth up to hundreds of millions of euros. For the industry in Poland, that transaction wasn’t just big – it was a signal that world-class science coming out of Poland could command world-class valuations.
He is joined by Dr. Anna Krause, an experienced R&D leader with a track record of running complex, multi-year development programs, and Dr. Joanna Lipner, whose strengths lie in understanding the drug development process end-to-end and translating it into effective execution, project management, and clear operational planning., as well as securing non-dilutive funding. Together, they form a leadership group that has repeatedly demonstrated the ability to take a project from concept to clinical reality.
This is a team that knows what it takes – because they’ve done it before.
Why Hard2beat Said “Yes”
Pikralida is tackling one of the biggest unsolved problems in medicine: how to protect the brain in the hours after a stroke or traumatic injury, and providing a fast, field-ready treatment for venomous snakebites. This is not a speculative idea – Pikralida is already a clinical-stage company, advancing therapies built on deep science with clear civilian and defense applications. And they’re doing it with a business model that doesn’t rely on a decade of burn – they’re building revenue early through the veterinary market.
We believe Pikralida could become one of the most exciting biotech stories coming out of Poland – and more importantly, a company whose products genuinely save lives, both human and canine, around the world.